Summit Therapeutics shares slide 14% after FDA rejects lung cancer drug
Summit Therapeutics shares fell 14% on Monday after the US Food and Drug Administration (FDA) declined to approve the company's experimental lung cancer drug, ivonescimab.
Latest news, updates and analysis on cancer treatment
Summit Therapeutics shares fell 14% on Monday after the US Food and Drug Administration (FDA) declined to approve the company's experimental lung cancer drug, ivonescimab.
Cancer survivors considering parenthood face a complex journey requiring medical guidance to determine safe timelines and potential fertility options.
On National Cancer Awareness Day, medical professionals and policymakers gathered at the Kadak Sehat Samvad event to highlight the importance of early detection and timely cancer treatment.